UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006294
Receipt number R000007452
Scientific Title Efficacy of Nilotinib in Patients with Chronic Myeloid Leukemia in chronic phase unachieved Complete Molecular Response
Date of disclosure of the study information 2011/09/06
Last modified on 2021/12/23 09:02:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of Nilotinib in Patients with Chronic Myeloid Leukemia in chronic phase unachieved Complete Molecular Response

Acronym

Efficacy of Nilotinib in Patients with CML unachieved CMR

Scientific Title

Efficacy of Nilotinib in Patients with Chronic Myeloid Leukemia in chronic phase unachieved Complete Molecular Response

Scientific Title:Acronym

Efficacy of Nilotinib in Patients with CML unachieved CMR

Region

Japan


Condition

Condition

Chronic myelogenous leukemia

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

CMR rate after Nlotinib treatment

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

CMR rate after Nlotinib treatmentat 2-year

Key secondary outcomes

The achievement of CMR time after the administration Nlotinib.
CMR rate after Nlotinib treatmentat 1-year.
Correlate trough levels of Nlotinib with clinical response.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Nlotinib treatment

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Chronic myelogenous leukemia in chronic-phase and accerated-phase
2)Patients with CML unachieved CMR who treatment 2y by TKI
3)Age &sup3;20 years
4)PS 0-2(ECOG)
5)No severe major organ dysfunction (AST,ALT, creatinine <3.0x ULN)
6) Written informed consent

Key exclusion criteria

1) Patients suspected in AP and BC
2) Pregnant and/or lactating woman
3) Severe psychological disorders
4) Uncontorlled complications

Target sample size

35


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaya Okada

Organization

Hyogo College of Medicine,

Division name

Division of Hematology, Department of Internal Medicine

Zip code


Address

1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

TEL

0798-45-6886

Email

masaya@hyo-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaya Okada

Organization

Hyogo College of Medicine

Division name

Division of Hematology, Department of Internal Medicine

Zip code


Address

1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

TEL

0798-45-6886

Homepage URL


Email

masaya@hyo-med.ac.jp


Sponsor or person

Institute

Hyogo College of Medicine

Institute

Department

Personal name



Funding Source

Organization

Hyogo College of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

兵庫医科大学 血液内科


Other administrative information

Date of disclosure of the study information

2011 Year 09 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 10 Month 15 Day

Date of IRB

2011 Year 05 Month 01 Day

Anticipated trial start date

2011 Year 05 Month 01 Day

Last follow-up date

2015 Year 01 Month 01 Day

Date of closure to data entry

2015 Year 01 Month 01 Day

Date trial data considered complete

2015 Year 01 Month 01 Day

Date analysis concluded

2015 Year 01 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 09 Month 06 Day

Last modified on

2021 Year 12 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007452


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name